Who is sponsoring NCT00225095?

NCT00225095 is sponsored by Mesoblast International Sàrl.

What drugs are being tested in NCT00225095?

Interventions in NCT00225095: Mesenchymal Stem Cells, Hyaluronan.

What condition does NCT00225095 study?

NCT00225095 studies Recovery Following Partial Medial Meniscectomy.

Is NCT00225095 still recruiting?

NCT00225095 is currently completed. Last updated 23 December 2021.

Last reviewed 2021-12-23 · How we verify

NCT00225095

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I/II, Randomized, Controlled, Double Blind, Study of Chondrogen - Adult Universal Cell Delivered by Intra-Articular Injection Following Meniscectomy in Patients 18-60 Years

Completed Phase 1/Phase 2 Last updated 23 December 2021

What this trial tests

Phase 1/Phase 2 trial testing Mesenchymal Stem Cells in Recovery Following Partial Medial Meniscectomy in 60 participants. Completed in 1 April 2008.

Timeline

1 September 2005

Primary endpoint
1 April 2008

1 April 2008

Quick facts

Lead sponsor	Mesoblast International Sàrl
Phase	Phase 1/Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	1 September 2005
Primary completion	1 April 2008
Estimated completion	1 April 2008
Sites	8 locations across United States

Drugs / interventions tested

Mesenchymal Stem Cells — full drug profile →
Hyaluronan — full drug profile →

Conditions studied

Recovery Following Partial Medial Meniscectomy — all drugs for Recovery Following Partial Medial Meniscectomy →

Sponsor

Mesoblast International Sàrl — full company profile →

Who can join

Adults 18 to 60, any sex, with Recovery Following Partial Medial Meniscectomy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Meniscal Volume
Time frame: 6 months
Changes in meniscal volume over the course of the study as determined by MRI

Sponsor's own description

The purpose of this study is to determine whether Chondrogen is a safe and effective post-operative treatment of the knee following menisectomy (the surgical removal of all or part of a torn meniscus).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Progress in intra-articular therapy.
Evans CH, Kraus VB, Setton LA. · · 2014 · cited 425× · PMID 24189839 · DOI 10.1038/nrrheum.2013.159
Advances in regenerative orthopedics.
Evans CH. · · 2013 · cited 56× · PMID 24182709 · DOI 10.1016/j.mayocp.2013.04.027
A systematic review of the concept and clinical applications of Bone Marrow Aspirate Concentrate in Orthopaedics.
Imam MA, Mahmoud SSS, Holton J, Abouelmaati D, et al · · 2017 · cited 33× · PMID 29792397 · DOI 10.1051/sicotj/2017007
Intra-articular injection choice for osteoarthritis: making sense of cell source-an updated systematic review and dual network meta-analysis.
Zhang Y, Yang H, He F, Zhu X. · · 2022 · cited 28× · PMID 36443838 · DOI 10.1186/s13075-022-02953-0
The Current Status of Clinical Trials on Biologics for Cartilage Repair and Osteoarthritis Treatment: An Analysis of ClinicalTrials.gov Data.
Zhang Z, Schon L. · · 2022 · cited 21× · PMID 35546280 · DOI 10.1177/19476035221093065
The Effectiveness and Safety of Mesenchymal Stem Cells in the Treatment of Osteoarthritis: A Systematic Review and Meta-analysis of 28 Randomized Controlled Trials.
Long Z, Zhang M, Zhang T, Zeng L, et al · · 2022 · cited 6× · PMID 36277037 · DOI 10.1155/2022/6151866

Verify or expand the search:

Other trials of Mesenchymal Stem Cells

Trials testing the same drug.

NCT06888973 — Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases · Phase 1, PHASE2 · enrolling by invitation
NCT06764329 — The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. · Phase 1, PHASE2 · enrolling by invitation
NCT06205342 — Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain · EARLY_PHASE1 · recruiting
NCT04519671 — Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease · Phase 1, PHASE2 · terminated
NCT04506073 — Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Park · Phase 2 · completed

Other Mesoblast International Sàrl trials

Trials by the same sponsor.

NCT04456439 — Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome i · no longer available
NCT04366830 — Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00225095 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mesoblast International Sàrl
Last refreshed: 23 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00225095.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing